Plain-English translation of NCT04616443 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of two treatments for advanced melanoma: OH2 (a genetically modified herpes virus injected directly into tumors) and HX008 (an immunotherapy drug given by injection). Researchers want to see if using these two treatments together is safe and more effective than existing options for patients whose melanoma has stopped responding to standard care.
Many melanoma patients don't respond well to current immunotherapy treatments or their cancer comes back after treatment. This trial is testing whether combining a virus-based injection with immunotherapy might help fight melanoma in a new way — by using the virus to trigger the immune system while the immunotherapy drug helps the body recognize and attack cancer cells.
You likely qualify if…
You likely don't qualify if…
You will receive injections of OH2 directly into your tumor starting in week 1, then every 2 weeks, along with HX008 injections beginning in week 2 and then every 3 weeks. Throughout the trial, you will have regular blood tests, imaging scans (like CT or MRI), and physical exams to monitor how well the treatment is working and check for any side effects. The trial will track how your tumors respond, how long you survive without disease progression, and your overall survival.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China